Finally, tetraspecific ANKET combining NKp46/CD16/CD20 and IL-2 are now being generated and are displaying strong preclinical antitumor efficacy against CD20+ tumor cells and an ability to increase NK cell proliferation (Demaria et al., unpublished data). This evidence concerns the gene FCGR3A and neoplasm.